Table 4.

Adjusted associations between IDH and 1-year mortality across predialysis SBP strata in the LDO cohort

DefinitionaPatients Meeting IDH Definition n (%)Adjusted ORb (95% CI) for Patients Meeting Versus Not Meeting IDH Definition
Pre-HD SBP≤129 mmHg (6448 patients)
 Nadir901393 (21.6%)1.32 (1.10 to 1.57)c
 Nadir1003096 (48.0%)1.23 (1.05 to 1.44)c
 Fall203018 (46.8%)1.08 (0.93 to 1.26)
 Fall301337 (20.7%)1.02 (0.85 to 1.23)
 Fall40440 (6.8%)1.30 (0.98 to 1.73)
 Fall50111 (1.7%)1.34 (0.80 to 2.23)
 Fall6035 (0.5%)1.51 (0.61 to 3.73)
 Fall30Nadir90847 (13.1%)1.06 (0.85 to 1.32)
 Fall20Nadir901136 (17.6%)1.18 (0.98 to 1.42)
Pre-HD SBP=130–159 mmHg (9759 patients)
 Nadir901043 (10.7%)1.28 (1.05 to 1.55)c
 Nadir1002703 (27.7%)1.14 (0.98 to 1.31)
 Fall208061 (82.6%)1.03 (0.86 to 1.24)
 Fall306176 (63.3%)1.06 (0.92 to 1.22)
 Fall403963 (40.6%)1.11 (0.97 to 1.28)
 Fall501977 (20.3%)1.04 (0.88 to 1.22)
 Fall60766 (7.9%)1.16 (0.92 to 1.46)
 Fall30Nadir901041 (10.7%)1.27 (1.05 to 1.54)c
 Fall20Nadir901041 (10.7%)1.27 (1.05 to 1.54)c
Pre-HD SBP≥160 mmHg (8307 patients)
 Nadir90578 (7.0%)1.08 (0.83 to 1.41)
 Nadir1001412 (17.0%)1.29 (1.07 to 1.56)c
 Fall207971 (96.0%)0.78 (0.55 to 1.11)
 Fall307386 (88.9%)1.13 (0.88 to 1.46)
 Fall406343 (76.4%)1.06 (0.88 to 1.28)
 Fall505039 (60.7%)1.13 (0.96 to 1.33)
 Fall603659 (44.1%)1.13 (0.96 to 1.32)
 Fall30Nadir90578 (7.0%)1.13 (0.86 to 1.48)
 Fall20Nadir90578 (7.0%)1.13 (0.86 to 1.48)
  • a Positive (+) IDH defined as nadir SBP<90 mmHg in ≥30% of exposure period dialysis sessions (versus not).

  • b Multivariate logistic models were adjusted for age (per 10 years), sex, race (black, nonblack, or missing), diabetes, heart failure, ischemic heart disease, cerebrovascular disease, peripheral vascular disease, vintage (≤0.9, 1–1.9, 2–3.9, or ≥4 years or missing), access (graft, fistula, or catheter), postdialysis weight (quartiles; kilograms), delivered treatment time (minutes), albumin (≤2.9, 3–3.9, or ≥4 g/dl or missing), hemoglobin (grams per deciliter), UF volume (liters), predialysis SBP (millimeters Hg), equilibrated Kt/V (<1.2, ≥1.2, or missing), missed sessions during exposure period (0, 1, 2, or ≥3), and use of α-adrenergic blocker, renin-angiotensin system blocker, β-blocker, calcium channel blocker, nitrates, and other antihypertensives.

  • c P value<0.05.